费城染色体阳性急性淋巴细胞白血病患者接受化疗联合酪氨酸激酶抑制剂治疗时,+der(22)t(9;22)和-9/9p与不良结局相关
在152例接受一线强化化疗联合伊马替尼、达沙替尼或帕纳替尼治疗的费城染色体阳性急性淋巴细胞白血病患者中,额外染色体异常见于118例(78%),整体与无额外染色体异常者相比RFS和OS无显著差异;但+der(22)t(9;22)和/或-9/9p且无高超二倍体的16%患者构成不良风险组,其5年RFS率33%对59%、5年OS率24%对63%均显著更短,多因素分析显示该组与更差RFS(HR 2.03)和OS(HR 2.02)独立相关;该不良风险在伊马替尼和达沙替尼组有预后意义,在帕纳替尼组无预后意义。
要点
- 152例Ph+ ALL接受化疗联合TKI,额外染色体异常见于118例(78%),整体与RFS(P=0.42)和OS(P=0.51)无显著差异。
- +der(22)t(9;22)和/或-9/9p且无高超二倍体见于16%患者,5年RFS率33%对59%(P=0.01)、5年OS率24%对63%(P=0.003)。
- 该不良风险组多因素分析RFS HR 2.03(95%CI 1.08-3.30,P=0.03)、OS HR 2.02(95%CI 1.10-3.71,P=0.02)。
核心结论
- 伴有+der(22)t(9;22)和/或-9/9p且无高超二倍体的Ph+ ALL患者在接受化疗联合TKI治疗时结局相对较差。
研究设计与样本
- 评估152例接受一线强化化疗联合伊马替尼(n=36)、达沙替尼(n=74)或帕纳替尼(n=42)治疗的Ph+ ALL患者中个体额外染色体异常的预后影响。
主要发现
- 额外染色体异常见于118例患者(78%),与无额外染色体异常者相比,RFS(P=0.42)和OS(P=0.51)均无显著差异。
- +der(22)t(9;22)和/或-9/9p且无高超二倍体见于16%患者,构成不良风险额外染色体异常组。
- 具有一个或多个不良风险额外染色体异常且无高超二倍体的患者5年RFS率33%对59%(P=0.01)、5年OS率24%对63%(P=0.003),均显著更短。
- 不良风险额外染色体异常在接受伊马替尼和达沙替尼的患者中有预后意义,在接受帕纳替尼的患者中无预后意义。
- 多因素分析显示不良风险额外染色体异常组与更差RFS(HR 2.03,95%CI 1.08-3.30,P=0.03)和OS(HR 2.02,95%CI 1.10-3.71,P=0.02)独立相关。
关键数值与推荐
- 不良风险额外染色体异常定义为+der(22)t(9;22)和/或-9/9p且无高超二倍体,见于16%的患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with chemotherapy plus a tyrosine kinase inhibitor (TKI), the prognostic impact of additional chromosomal abnormalities (ACAs) is not well-established. We evaluated the prognostic impact of individual ACAs in 152 patients with Ph+ ALL receiving first-line intensive chemotherapy plus either imatinib (n = 36), dasatinib (n = 74), or ponatinib (n = 42). ACAs were identified in 118 patients (78%). Compared to outcomes of patients without ACAs, ACAs were not associated with differences in either relapse-free survival (RFS; P = 0.42) or overall survival (OS; P = 0.51). When individual ACAs were evaluated, +der(22)t(9;22) and/or -9/9p in the absence of high hyperdiploidy (HeH) was present in 16% of patients and constituted a poor-risk ACA group. Patients with one or more poor-risk ACAs in the absence of HeH had significantly shorter RFS (5-year RFS rate 33% versus 59%, P = 0.01) and OS (5-year OS rate 24% versus 63%, P = 0.003). Poor-risk ACAs were prognostic in patients who received imatinib and dasatinib but not in those who received ponatinib. By multivariate analysis, this poor-risk ACA group was independently associated with worse RFS (HR 2.03 [95% CI 1.08-3.30], P = 0.03) and OS (HR 2.02 [95% CI 1.10-3.71], P = 0.02). Patients with Ph+ ALL who have +der(22)t(9;22) and/or -9/9p in the absence of HeH have relatively poor outcomes when treated with chemotherapy plus a TKI.
引用
- Short NJ, Kantarjian HM, Sasaki K, et al. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017. PMID: 28006851. doi:10.1002/ajh.24625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。